Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Inks Pact With EU For Coronavirus Vaccine

Deal Is For At Least 300 Million Doses

Executive Summary

The agreement will give all EU member states the option to access the drug major's investigational COVID-19 vaccine dubbed AZD1222 "in an equitable manner at no profit during the pandemic."

You may also be interested in...



Coronavirus Notebook: UK Ups Vaccine Efforts & Calls For More Candidate Therapies

The UK has been stepping up its COVID-19 activity in recent days, ordering more vaccines, encouraging more volunteers to join clinical trials, and expanding its RECOVERY platform for potential new coronavirus therapies. But the government's sudden decision to replace Public Health England with a new institute has raised some concerns within the biopharma industry.

Coronavirus Update: J&J’s Single Dose Stands Out From COVID Vaccine Crowd

J&J is a few months behind companies like Moderna, Pfizer and AstraZeneca in the race to develop a vaccine, but a safe and effective single dose immunization would be a game changer.

EU Takes Over COVID-19 Vaccine Negotiations, But Lags Behind US

A quartet of EU countries started vaccine procurement talks with AstraZeneca, but are now allowing the European Commission to take over negotiations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel